Incomplete HPV vaccination may offer some protection

July 24, 2014

Minority women who received the Human Papillomavirus Vaccination (HPV) even after becoming sexually active had lower rates of abnormal Pap test results than those who were never vaccinated. These findings appear in the journal Sexually Transmitted Diseases.

Researchers from Boston University School of Public Health and School of Medicine conducted a cross-sectional study of 235 women age 21 to 30 undergoing routine cervical cytology testing. HPV status and demographic and behavioral characteristics were self-reported and verified with .

"Although data clearly indicate better immune responses and vaccine efficacy against both genital warts and cervical dysplasia when vaccination occurs before age 14, this study suggests that HPV vaccination may be effective in reducing abnormal Pap test results even after sexual debut," explained co-author Rebecca Perkins, MD, MSc, assistant professor of Obstetrics and Gynecology at Boston University School of Medicine and a gynecologist at Boston Medical Center.

At the time of the study, 41 percent had received at least one HPV vaccination; 97 percent of women were vaccinated after sexual debut. Ten percent of women had an abnormal cervical cytology result. The prevalence of abnormal cytology was 65 percent lower in women who received at least one HPV vaccination as compared to unvaccinated women.

According to the researchers continued surveillance of HPV vaccination is necessary to identify clinical benefits, particularly given the low rate of vaccine uptake and completion and vaccination of many young women after sexual debut. "Studies should continue to compare vaccine effectiveness before and after sexual debut and by doses received and to explore the role of herd immunity," added Perkins.

Explore further: What's the best test for cervical cancer? Pap, HPV or both?

Related Stories

What's the best test for cervical cancer? Pap, HPV or both?

June 9, 2014
Should U.S. women be screened for cervical cancer with Pap tests, HPV tests or both? According to researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) while the merits of screening ...

Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine

July 24, 2014
A long-term follow-up study (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity and safety of GlaxoSmithKline's human papilloma virus (HPV) vaccine Cervarix. Women vaccinated with the HPV-16/18 AS04-adjuvanted ...

Beliefs about HPV vaccine do not lead to initiation of sex or risky sexual behavior

February 3, 2014
A new study may alleviate concerns that the human papillomavirus (HPV) vaccine leads to either the initiation of sex or unsafe sexual behaviors among teenage girls and young women.

Study does not find increased risk of blood clot following HPV vaccination

July 8, 2014
Although some data has suggested a potential association between receipt of the quadrivalent human papillomavirus (HPV) vaccination and subsequent venous thromboembolism (VTE; blood clot), an analysis that included more than ...

HPV vaccination is associated with reduced risk of cervical lesions in Denmark

February 19, 2014
A reduced risk of cervical lesions among Danish girls and women at the population level is associated with use of a quadrivalent HPV vaccine after only six years, according to a new study published February 19 in the Journal ...

Researchers find moral beliefs barrier to HPV vaccine

July 7, 2014
A survey of first-year Grand Valley State University students showed the biggest barrier to receiving a Human Papillomavirus (HPV) vaccine was moral or religious beliefs, or a perceived promotion of sexual behavior, according ...

Recommended for you

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.